Poster: IBCL-123 inMIND: A Phase 3 Study of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)
Clinical Lymphoma Myeloma and Leukemia（2022）
关键词
IBCL, non-Hodgkin lymphoma, CD19, marginal, zone lymphoma, follicular lymphoma, Phase III
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要